Researchers compared Amgen Inc."s denosumab and Novartis AG"s Zometa [zoledronic acid] in the treatment of bone metastases in 1,776 advanced cancer patients and found that both drugs had similar effects in delaying patients" initial and subsequent bone injuries. The trial is the second of three planned studies testing the drug in patients with cancer that has spread to their bones. Denosumab is also being reviewed as a treatment for osteoporosis and bone loss caused by hormone treatment in patients with breast and prostate cancer by the FDA.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지